Alpha Tau(US:DRTS) Globenewswire·2026-03-31 13:15Core Insights - Alpha Tau Medical Ltd. has announced that an abstract detailing results from two clinical trials on its alpha-radiation cancer therapy, Alpha DaRT, for pancreatic cancer has been accepted for oral presentation at Digestive Disease Week (DDW) 2026, marking a significant recognition of its technology in a major gastroenterology conference [1][2][3] Company Overview - Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company founded in 2016, focusing on the research, development, and potential commercialization of Alpha DaRT for treating solid tumors [5] - The Alpha DaRT technology was initially developed by Professors Itzhak Kelson and Yona Keisari from Tel Aviv University [5] Technology Details - Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed for highly potent and conformal alpha-irradiation of solid tumors through intratumoral delivery of radium-224 sources, aiming to primarily affect the tumor while sparing surrounding healthy tissue [6] Clinical Trial Presentation - The abstract titled "Updated Results of Feasibility, Safety, and Tumor Control in Two First-In-Human Trials of a Novel Alpha-Emitting Radionuclide for Pancreatic Adenocarcinoma" will be presented on May 2, 2026, at 10:30 am (Central) during the Pancreatic Cancer I: Diagnosis and Treatment session [2] - The presentation will be led by Dr. Harold Jacob, the Principal Investigator, and is based on combined data from two clinical protocols conducted at Hadassah Medical Center in Jerusalem [2] Significance of Presentation - The acceptance of the abstract for oral presentation at DDW is viewed as a milestone for Alpha Tau, indicating growing recognition of the potential of Alpha DaRT to address pancreatic cancer, particularly for patients deemed inoperable at diagnosis [3] - Dr. Jacob emphasized the importance of this presentation as it represents the first clinical data of Alpha DaRT in pancreatic cancer to be shared at a major gastroenterology forum [3]